Detalhe da pesquisa
1.
A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leukemia.
Biol Blood Marrow Transplant
; 22(4): 698-704, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-26785332
2.
Sequential administration of sargramostim and filgrastim in pediatric allogeneic stem cell transplantation recipients undergoing myeloablative conditioning.
Pediatr Transplant
; 13(4): 464-74, 2009 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-18785912
3.
Identification and Management: Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease Eelated to Hematopoietic Stem Cell Transplantationâ©.
Clin J Oncol Nurs
; 22(1): E7-E17, 2018 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29350698
4.
Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia.
Clin Cancer Res
; 11(19 Pt 2): 7164s-7170s, 2005 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16203817
5.
A low incidence of nontuberculous mycobacterial infections in pediatric hematopoietic stem cell transplantation recipients.
Biol Blood Marrow Transplant
; 12(11): 1188-97, 2006 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-17085312
6.
A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients.
Biol Blood Marrow Transplant
; 10(4): 246-58, 2004 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-15077223